Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates

Journal of Viral Hepatitis

Volumn 18, Issue 12, 2011, Pages 861-870

  Sun, S C C ^a   Bae, A ^a   Qi, X ^a   Harris, J ^a   Wong, K A ^a   Miller, M D ^a   Mo, H ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

baseline; HCV; nonnucleoside inhibitor; NS5B

Indexed keywords

BENZOFURAN DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B; THENOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; GENE ISOLATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; MICROBIAL SENSITIVITY TESTS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 79960468479     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01396.x     Document Type: Article

References (39)

1. Seeff LB,. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl. 1): S35-S46. (Pubitemid 35253462)
2. Purcell RH,. Hepatitis C virus: historical perspective and current concepts. FEMS Microbiol Rev 1994; 14 (3): 181-191.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347 (13): 975-982.
4. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (Suppl. 1): S237-S244. (Pubitemid 35253486)
5. Foster GR,. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24 (Suppl. 2): 97-104. (Pubitemid 39180712)
6. Foster GR,. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20 (8): 825-830. (Pubitemid 39424889)
7. Kwong AD, McNair L, Jacobson I, George S,. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Current Opin Pharmacol 2008; 8 (5): 522-531.
8. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46 (3): 631-639. (Pubitemid 47436107)
9. Lawitz E, Rodriguez-Torres M, Cohen D, et al. Dose-dependent decrease in HCV viral load following two-day monotherapy with ABT-333 in treatment-naive, HCV genotype 1-infected subjects. 4th International Workshop on Hepatitis C resistance & new compounds, June, 25-26th, Boston, USA 2009; Abstract# 18.
10. Lawitz E, Rodriguez-Torres M, DeMicco M, et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitors, in chronic Hepatitis C patients, 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark, Absract# 1055. J Hepatol 2009; 50: S384.
11. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132 (4): 1270-1278. (Pubitemid 46627577)
12. Klein CE, Cohen D, Menon R, et al. Safety, tolerability and antiviral activity of the HCV polymerase inhibitor ABT-072 following single and multiple dosing in healthy adult volunteers and two days of dosing in treatment-naive HCV genotype-1-infected subjects. Dec 6-10, Kohala Coast, Hawaii, Abstract # 56. Hep DART 2009; 5 (Suppl. 1): 52-53.
13. Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007; 51 (2): 503-509. (Pubitemid 46185267)
14. Toniutto P, Fabris C, Bitetto D, Fumolo E, Fornasiere E, Pirisi M,. R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs 2008; 11 (10): 738-749.
15. Brown NA,. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009; 18 (6): 709-725.
16. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008; 52 (12): 4356-4369.
17. O'Brien C, Godofsky E, Rodriguez-Torres M, et al. Randomized trial of Valopicitabine (NM283), alone or with Peg-Interferon, vs. retreatment with Peg-Interferon plus Ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: first interim results. 56th Annual Meeting of AASLD Hepatology 42 (S1), 234A (Abstract 96). 2005.
18. Afdhal N, Godofsky E, Dienstag J, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. 55th Annual Meeting of AASLD Hepatology 40 (S4), 726A (Abstract LB03). 2004.
19. Love RA, Parge HE, Yu X, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 2003; 77 (13): 7575-7581. (Pubitemid 36734527)
20. Beaulieu PL,. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007; 8 (8): 614-634. (Pubitemid 47205246)
21. Sarisky RT,. Non-nucleoside inhibitors of the HCV polymerase. J Antimicrob Chemother 2004; 54 (1): 14-16. (Pubitemid 39028962)
22. Wagner R, Maring C, Flentge P, et al. Preclinical characterization of ABT-333 and ABT-072: novel non-nucleoside HCV NS5B polymerase inhibitors. Dec 6-10, Kohala Coast, Hawaii, Abstract # 108. Hep DART 2009; 5 (Suppl. 1): 100-101.
23. Lu L, Dekhtyar T, Masse S, et al. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 2007; 76 (1): 93-97. (Pubitemid 47176691)
24. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005; 49 (10): 4305-4314. (Pubitemid 41400978)
25. Showalter RE, Thompson PA, Steffy KR, Appleman JR,. ANA598 displays potent in vitro antiviral activity against diverse clinical isolates of genotype 1 HCV in a transient replicon shuttle vector system. American Association for the Study of Liver Diseases (AASLD), Boston, Oct 30-Nov. 3, Abstract# 1586. Hepatology 2009; 50 (Suppl. 4): 1037A.
26. Kneteman NM, Howe AY, Gao T, et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009; 49 (3): 745-752.
27. Flint M, Mullen S, Deatly AM, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009; 53 (2): 401-411.
28. Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005; 280 (47): 39260-39267. (Pubitemid 41713879)
29. Cooper C, Lawitz EJ, Ghali P, et al. Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 2009; 51 (1): 39-46.
30. Shi ST, Herlihy KJ, Graham JP, et al. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2008; 52 (2): 675-683. (Pubitemid 351170844)
31. Shi ST, Herlihy KJ, Graham JP, et al. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009; 53 (6): 2544-2552.
32. Herring BL, Tsui R, Peddada L, Busch M, Delwart EL,. Wide range of quasispecies diversity during primary hepatitis C virus infection. J Virol 2005; 79 (7): 4340-4346. (Pubitemid 40388371)
33. Zhang YY, Lok AS, Chan DT, Widell A,. Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. J Clin Microbiol 1995; 33 (11): 2931-2934.
34. Simmonds P,. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999; 31 (Suppl. 1): 54-60. (Pubitemid 30002692)
35. Simmonds P,. The origin and evolution of hepatitis viruses in humans. J Gen Virol 2001; 82 (Pt 4): 693-712. (Pubitemid 32280027)
36. Friebe P, Lohmann V, Krieger N, Bartenschlager R,. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75 (24): 12047-12057. (Pubitemid 33115877)
37. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R,. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003; 77 (5): 3007-3019. (Pubitemid 36228086)
38. Middleton T, He Y, Pilot-Matias T, et al. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 2007; 145 (2): 137-145. (Pubitemid 47332699)
39. Le Pogam S, Seshaadri A, Kosaka A, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61 (6): 1205-1216. (Pubitemid 351753583)